Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 21;158(10):709-17.
doi: 10.7326/0003-4819-158-10-201305210-00005.

Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer

Timothy J Daskivich  1 , Kang-Hsien Fan, Tatsuki Koyama, Peter C Albertsen, Michael Goodman, Ann S Hamilton, Richard M Hoffman, Janet L Stanford, Antoinette M Stroup, Mark S Litwin, David F Penson
Affiliations

Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer

Timothy J Daskivich et al. Ann Intern Med. .

Abstract

Background: Accurate estimation of life expectancy is essential to offering appropriate care to men with early-stage prostate cancer, but mortality risks associated with comorbidity are poorly defined.

Objective: To determine the effect of age, comorbidity, and tumor risk on other-cause and prostate cancer-specific mortality in men with early-stage disease.

Design: Prospective cohort study.

Setting: A nationally representative, population-based cohort.

Patients: 3183 men with nonmetastatic prostate cancer at diagnosis.

Measurements: Baseline self-reported comorbidity (scored as a count of 12 major comorbid conditions), tumor characteristics, initial treatment, and overall and disease-specific mortality through 14 years of follow-up. Survival analyses that accounted for competing risks were performed.

Results: Fourteen-year cumulative other-cause mortality rates were 24%, 33%, 46%, and 57% for men with 0, 1, 2, and 3 or more comorbid conditions, respectively. For men diagnosed at age 65 years, subhazard ratios for other-cause mortality among those with 1, 2, or 3 or more comorbid conditions (vs. none) were 1.2 (95% CI, 1.0 to 1.4), 1.7 (CI, 1.4 to 2.0), and 2.4 (CI, 2.0 to 2.8), respectively. Among men with 3 or more comorbid conditions, 10-year other-cause mortality rates were 26%, 40%, and 71% for those aged 60 years or younger, 61 to 74 years, and 75 years or older at diagnosis, respectively. Prostate cancer-specific mortality was minimal in patients with low-risk (3%) and intermediate-risk (7%) disease but appreciable in those with high-risk disease (18%) and did not vary by number of comorbid conditions (10% to 11% in all groups).

Limitation: Comorbid conditions were self-reported.

Conclusion: Older men with multiple major comorbid conditions are at high risk for other-cause mortality within 10 years of diagnosis and should consider this information when deciding between conservative management and aggressive treatment for low- or intermediate-risk prostate cancer.

Primary funding source: National Cancer Institute.

PubMed Disclaimer

Figures

Appendix Figure
Appendix Figure. Study flow diagram
PCOS = Prostate Cancer Outcomes Study.
Figure 1
Figure 1
Cumulative incidence curves for other-cause and prostate cancer–specific mortality, by number of comorbid conditions.
Figure 2
Figure 2
Competing-risks model depicting cumulative incidence of other-cause and prostate cancer–specific mortality, by number of comorbid conditions, for men aged <60 y (A and B), 60 to 70 y (C and D), and >70 y (E and F).
Figure 3
Figure 3
Competing-risks model depicting cumulative incidence of other-cause and prostate cancer–specific mortality, by D'Amico risk criteria, for men aged <60 y (A and B), 60 to 70 y (C and D), and >70 y (E and F).
See this image and copyright information in PMC

Comment in

Summary for patients in

References

    1. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–17. [PMID: 21542742] - PubMed
    1. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162–200. [PMID: 20141676] - PubMed
    1. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cook-son MS, et al. AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–31. [PMID: 17509297] - PubMed
    1. Walz J, Suardi N, Shariat SF, Jeldres C, Perrotte P, Graefen M, et al. Accuracy of life tables in predicting overall survival in patients after radical pros-tatectomy. BJU Int. 2008;102:33–8. [PMID: 18384631] - PubMed
    1. Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011;117:2058–66. [PMID: 21523717] - PubMed

Publication types